Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma : A practical resource for nurses
Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improv...
Gardado en:
| Auteurs principaux: | , |
|---|---|
| Formato: | Livre numérique |
| Idioma: | Anglais |
| Publicado: |
Basel :
S. Karger
2021.
Basel : |
| Acceso en liña: | https://www.karger.com/Book/Home/280784 Accès Université d'Orléans et IFPM |
| Nota: |
Karger Fast Facts |
| Autres localisations: | Voir dans le Sudoc |
| Edition sous un autre format: | • Fast Facts: CAR T-Cell Therapy in Diffuse Large B-Cell Lymphoma, 9783318070248 |
| Résumé: | Diffuse large B-cell lymphoma (DLBCL) is the most common form of high-grade non-Hodgkin lymphoma. While treatment with immunochemotherapy has generally shown good outcomes, specific subgroups of patients with high-risk disease have an unfavorable prognosis. Extensive efforts have been made to improve outcomes in these patients. As such, CD19-targeted chimeric antigen receptor (CAR) T-cell therapy has become the new standard of care for patients with relapsed or refractory DLBCL after at least two prior lines of therapy. It is an exciting new therapeutic intervention that is integral to the concept of personalized medicine |
|---|---|
| descrición da copia: | Karger Fast Facts |
| ISBN: | 9783318069358 |
| Acceso: | Accès libre pour tout établissement ou utilisateur ayant un compte sur la plateforme de l'éditeur |